Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Doravirine in Severe Renal Impairment
NCT02641067Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of doravirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity, Plasma Concentration of Doravirine at 24 Hours Postdose and 6 more. Started Jan 2016; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02641067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641067.